Study examines association between finasteride and suicidality, depression, and anxiety
“What we wanted to do was to substantiate any difference between BPH and alopecia with finasteride and also people who are concomitantly taking testosterone for hypogonadism,” says Kevin J. Campbell, MD, MS.
In this video, Kevin J. Campbell, MD, MS, discusses the background and findings of the study, “Finasteride-Associated Suicide and Depression in Men Treated for Hypogonadism and Impotence,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Campbell is an assistant professor in the department of urology at the University of Florida, Gainesville.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
